Key result
Integrating evidence-based guidelines with innovative reversal agents, personalized medicine, AI, and nanotechnology can ensure patient safety and minimize bleeding risks in orthopedic surgery.
Why the study?
Anticoagulation therapy during major orthopedic surgeries presents a clinical challenge due to the competing risks of thrombotic events and bleeding complications.
The integration of specific DOAC reversal agents, pharmacogenomics, AI, and nanotechnology represents a promising new era for optimizing perioperative anticoagulation management and minimizing bleeding risks in orthopedic surgery.
AIM: The administration of anticoagulation therapy during major orthopedic surgeries is a clinical challenge due to the risk of thrombotic events and bleeding complications. This review aims to evaluate the current strategies and emerging developments in perioperative anticoagulation reversal. METHODS: We conducted a literature review on the management of perioperative anticoagulant therapy, which included the current status of anticoagulant reversal agents, as well as personalized medicine, pharmacogenomics, artificial intelligence (AI), and novel drug delivery systems. RESULTS: The review indicates that reversal agents such as idarucizumab and andexanet alfa are crucial in managing bleeding associated with direct oral anticoagulants (DOACs). Personalized medicine, guided by pharmacogenomics, allows for tailored anticoagulation regimens. AI and machine learning (ML) algorithms can enhance the predictive capabilities for bleeding and thrombotic risks. Additionally, nanotechnology and biomarkers offer innovative approaches to drug delivery and personalized treatment. CONCLUSIONS: Integrating evidence-based guidelines with innovative reversal agents, personalized medicine, AI and nanotechnology opens a new era in perioperative anticoagulation management. These advancements can ensure patient safety, minimize bleeding risks, and improve surgical outcomes. Future research should focus on the clinical validation of these strategies to ensure their effectiveness across diverse patient populations.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2024) conducted a review in Orthopedic surgery requiring perioperative anticoagulation reversal. Anticoagulant reversal strategies (idarucizumab, andexanet alfa, personalized medicine, AI, nanotechnology) was evaluated. Integrating evidence-based guidelines with innovative reversal agents, personalized medicine, AI, and nanotechnology can ensure patient safety and minimize bleeding risks in orthopedic surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: